A Boston-based nonprofit that is focused on global public health has laid off around 1,100 employees due to the Trump ...

End-of-Year Report showcases significant changes in the tax landscape, indicating additional complexity in 2025KING OF PRUSSIA, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:VERX) (“Vertex” or the ...

The current consensus EPS estimate is $0.01 on $63.72 million in revenues for the coming quarter and -$0.07 on $251.25 million in revenues for the ... Another stock from the same industry, Vertex ...

As of 6 February at 12:45:41 pm GMT-5. Market open. Vertex Baseline Delta ...

As of 30 January at 11:30:53 am GMT-5. Market open. Vertex Baseline Delta ...

Revenue $2.91 billion $2.78 billion $2.52 billion 15.7% Net Income (non-GAAP) $1.04 billion N/A $1.10 billion (5.5%) R&D and SG&A expenses (non-GAAP) $1.21 billion N/A $984 million 22.9% Vertex ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

KING OF PRUSSIA, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today released the findings of ...

Here's why they think Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX) could trounce the market in 2025. David Jagielski (Eli Lilly): For years ...

The hormones you replace are not as protective as the hormone's you used to naturally produce, Shankar said. In fact, there ...